Stephen Hansen

Bain Capital’s Adam Koppel on private equity’s role in biotech Koppel shares his expectations for financial markets, dealmaking in 2026 Private equity’s expanding role in biopharma as a growth equity investor reflects both the maturation of the life scien... See more

FDA’s moving goalposts & China’s innovation arc — a BioCentury podcast Plus: Can CRISPR therapies be commercially successful? And what’s next for NLRP3 inhibitors in obesity? A baffling FDA decision to issue a complete response letter for a pediatric ... See more

Cautious optimism and M&A momentum — A BioCentury podcast Takeaways from London Life Sciences Week, including expectations for M&A, venture financing next year There is cautious optimism around continued M&A momentum and the public equities ma... See more

Is this the U.K.’s moment for biotech? A BioCentury podcast Takeaways from the inaugural Grand Rounds — Europe Is this the U.K.’s moment to capitalize on its biotech ecosystem? That was one of the primary themes discussed at the debut Grand Rounds — Europ... See more